Literature DB >> 23561394

Temporally distinct cognitive effects following acute administration of ketamine and phencyclidine in the rat.

Francois Gastambide1, Stephen N Mitchell, Trevor W Robbins, Mark D Tricklebank, Gary Gilmour.   

Abstract

Non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonists such as phencyclidine (PCP) and ketamine are commonly and interchangeably used to model aspects of schizophrenia in animals. We compared here the effects of acute administration of these compounds over a range of pre-treatment times in tests of instrumental responding (VI 30s response schedule), simple reaction time (SRT) and cognitive flexibility (reversal learning and attentional set shifting digging task) in rats. At standard pre-treatment times (15-30 min), both ketamine and PCP produced overall response suppression in VI 30 and increased reaction times in SRT suggesting that any concomitant cognitive performance deficits are likely to be confounded by motor and/or motivational changes. However, the use of extended pre-treatment times produced deficits in cognitive flexibility measured up to 4h after drug administration in the absence of motor/motivational impairment. Generally, PCP increased impulsive responding in the SRT indicating a possible loss of inhibitory response control that may have contributed to deficits observed in reversal learning and attentional set-shifting. In contrast to PCP, ketamine did not have the same effect on impulsive responding, and possibly as a consequence produced more subtle cognitive deficits in attentional set-shifting. In summary, acute treatment with NMDAR antagonists can produce cognitive deficits in rodents that are relevant to schizophrenia, provided that motor and/or motivational effects are allowed to dissipate. The use of longer pre-treatment times than commonly employed might be advantageous. Also, ketamine, which is more frequently used in clinical settings, did not produce as extensive cognitive deficits as PCP.
Copyright © 2013 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Attention; Executive control; Motor; NMDA; NMDAR; PCP; Pharmacokinetics; SRT; Schizophrenia; VI; non-competitive N-methyl-d-aspartate receptor; phencyclidine; simple reaction time; variable interval

Mesh:

Substances:

Year:  2013        PMID: 23561394     DOI: 10.1016/j.euroneuro.2013.03.002

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  17 in total

Review 1.  Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.

Authors:  Maria R Dauvermann; Graham Lee; Neil Dawson
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

Review 2.  Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia.

Authors:  Cassandra J Hatzipantelis; Monica Langiu; Teresa H Vandekolk; Tracie L Pierce; Jess Nithianantharajah; Gregory D Stewart; Christopher J Langmead
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-28

3.  Dissociation of mGlu2/3 agonist effects on ketamine-induced regional and event-related oxygen signals.

Authors:  Jennifer Francois; Francois Gastambide; Michael Warwick Conway; Mark Tricklebank; Gary Gilmour
Journal:  Psychopharmacology (Berl)       Date:  2015-05-06       Impact factor: 4.530

4.  Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway.

Authors:  Julianne D Jett; Angela M Boley; Milena Girotti; Amiksha Shah; Daniel J Lodge; David A Morilak
Journal:  Psychopharmacology (Berl)       Date:  2015-05-20       Impact factor: 4.530

5.  Ketamine Suppresses the Ventral Striatal Response to Reward Anticipation: A Cross-Species Translational Neuroimaging Study.

Authors:  Jennifer Francois; Oliver Grimm; Adam J Schwarz; Janina Schweiger; Leila Haller; Celine Risterucci; Andreas Böhringer; Zhenxiang Zang; Heike Tost; Gary Gilmour; Andreas Meyer-Lindenberg
Journal:  Neuropsychopharmacology       Date:  2015-09-21       Impact factor: 7.853

6.  Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys.

Authors:  Alvin V Terry; Marc Plagenhoef; Patrick M Callahan
Journal:  Psychopharmacology (Berl)       Date:  2015-11-27       Impact factor: 4.530

7.  Effects of N-Methyl-D-aspartate (NMDA) antagonists ketamine, methoxetamine, and phencyclidine on the odor span test of working memory in rats.

Authors:  Michael J Mathews; Ralph N Mead; Mark Galizio
Journal:  Exp Clin Psychopharmacol       Date:  2018-02       Impact factor: 3.157

8.  Losing control under ketamine: suppressed cortico-hippocampal drive following acute ketamine in rats.

Authors:  Rosalyn J Moran; Matthew W Jones; Anthony J Blockeel; Rick A Adams; Klaas E Stephan; Karl J Friston
Journal:  Neuropsychopharmacology       Date:  2014-07-23       Impact factor: 7.853

9.  Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats.

Authors:  Agnieszka Nikiforuk; Tomasz Kos; Katarzyna Fijał; Małgorzata Hołuj; Dominik Rafa; Piotr Popik
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

10.  Assessing the Cognitive Translational Potential of a Mouse Model of the 22q11.2 Microdeletion Syndrome.

Authors:  Simon Ro Nilsson; Kim Fejgin; Francois Gastambide; Miriam A Vogt; Brianne A Kent; Vibeke Nielsen; Jacob Nielsen; Peter Gass; Trevor W Robbins; Lisa M Saksida; Tine B Stensbøl; Mark D Tricklebank; Michael Didriksen; Timothy J Bussey
Journal:  Cereb Cortex       Date:  2016-08-09       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.